Loading...
•
Sep 30
Zimmer Biomet Q3 2025 Earnings Report
Zimmer Biomet reported Q3 2025 results with strong U.S. growth and robust EPS performance, despite regional weaknesses.
Key Takeaways
Zimmer Biomet delivered solid Q3 results with $2.0B in revenue and strong adjusted EPS of $1.90. Net income reached $230.9M. U.S. sales were the main growth driver, while Latin America and parts of Europe saw softness.
Revenue rose to $2.001B in Q3, driven by 10.6% growth in the U.S.
Net income totaled $230.9M, with adjusted EPS of $1.90.
S.E.T. segment saw standout performance with $541.5M in sales.
Launched new robotic and iodine-treated implants to bolster future growth.
Zimmer Biomet
Zimmer Biomet
Zimmer Biomet Revenue by Segment
Zimmer Biomet Revenue by Geographic Location
Revenue by Segment
Knees Revenue
CapyFin.comHips Revenue
CapyFin.comS.E.T. Revenue
CapyFin.comTech, Cement & Surgical Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Zimmer Biomet maintained full-year revenue and EPS guidance while slightly narrowing expectations for constant and organic constant currency growth.
Positive Outlook
- Maintained reported revenue growth guidance at 6.7% to 7.7%
- Adjusted EPS guidance reaffirmed at $8.10 to $8.30
- Ongoing momentum in U.S. sales performance
- Launch of iodine-treated implants adds product differentiation
- Innovation pipeline includes autonomous robotics for orthopedics
Challenges Ahead
- Narrowed constant currency revenue growth to 6.2% to 6.7%
- Organic constant currency growth trimmed to 3.5% to 4.0%
- Weakness in Latin America and Emerging Markets
- Softness in non-core businesses late in the quarter
- Continued macroeconomic pressures in some regions
Revenue & Expenses
Visualization of income flow from segment revenue to net income